Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma

Matthew S McKinney, Anne W Beaven Division of Hematologic Malignancies, Department of Medicine, Duke University Medical Center, Durham, NC, USA Abstract: Most cases of indolent non-Hodgkin lymphoma (NHL) are incurable with standard chemoimmunotherapy approaches, and patients with relapsed/refracto...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McKinney MS, Beaven AW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/b9627e99554348259522087327de8adb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b9627e99554348259522087327de8adb
record_format	dspace
spelling	oai:doaj.org-article:b9627e99554348259522087327de8adb2021-12-02T06:19:37ZYttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma1179-9889https://doaj.org/article/b9627e99554348259522087327de8adb2014-08-01T00:00:00Zhttp://www.dovepress.com/yttrium-90-ibritumomab-tiuxetan-in-the-treatment-of-non-hodgkin-lympho-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889 Matthew S McKinney, Anne W Beaven Division of Hematologic Malignancies, Department of Medicine, Duke University Medical Center, Durham, NC, USA Abstract: Most cases of indolent non-Hodgkin lymphoma (NHL) are incurable with standard chemoimmunotherapy approaches, and patients with relapsed/refractory disease have progressively shorter remissions and short survival with subsequent chemotherapy regimens. This may potentially be overcome with diversification of treatment strategies to include other modalities including radiotherapy, small molecule signaling transduction inhibitors, or high-dose chemotherapy with stem cell support. Yttrium-90 ibritumomab tiuxetan (Zevalin®) is a novel treatment entity for indolent NHL. A radiolabeled antibody conjugate, it consists of a murine anti-CD20 antibody linked to a chelator molecule, tiuxetan, which is bound to radioactive yttrium. Yttrium-90 ibritumomab tiuxetan is approved for use as consolidation after initial treatment of follicular lymphoma as well as single-agent therapy in relapsed/refractory B-cell NHL. Responses are seen even in patients refractory to conventional cytotoxic chemotherapy and rituximab in both indolent and aggressive NHL subtypes. Recent clinical studies have also shown that yttrium-90 ibritumomab tiuxetan has significant activity when combined with novel targeted small molecular inhibitors as well as in autologous and allogeneic transplantation regimens. Here we review the biology underlying the efficacy of yttrium-90 ibritumomab tiuxetan in NHL and present an overview of the clinical experience with this agent in NHL. Finally, we discuss the current role of yttrium-90 ibritumomab tiuxetan in the armamentarium of treatments for NHL and possibilities for incorporating it into future NHL treatment algorithms. Keywords: non-Hodgkin lymphoma, indolent, CD20, radioimmunotherapy, ibritumomab tiuxetanMcKinney MSBeaven AWDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 45-59 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 McKinney MS Beaven AW Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
description	Matthew S McKinney, Anne W Beaven Division of Hematologic Malignancies, Department of Medicine, Duke University Medical Center, Durham, NC, USA Abstract: Most cases of indolent non-Hodgkin lymphoma (NHL) are incurable with standard chemoimmunotherapy approaches, and patients with relapsed/refractory disease have progressively shorter remissions and short survival with subsequent chemotherapy regimens. This may potentially be overcome with diversification of treatment strategies to include other modalities including radiotherapy, small molecule signaling transduction inhibitors, or high-dose chemotherapy with stem cell support. Yttrium-90 ibritumomab tiuxetan (Zevalin®) is a novel treatment entity for indolent NHL. A radiolabeled antibody conjugate, it consists of a murine anti-CD20 antibody linked to a chelator molecule, tiuxetan, which is bound to radioactive yttrium. Yttrium-90 ibritumomab tiuxetan is approved for use as consolidation after initial treatment of follicular lymphoma as well as single-agent therapy in relapsed/refractory B-cell NHL. Responses are seen even in patients refractory to conventional cytotoxic chemotherapy and rituximab in both indolent and aggressive NHL subtypes. Recent clinical studies have also shown that yttrium-90 ibritumomab tiuxetan has significant activity when combined with novel targeted small molecular inhibitors as well as in autologous and allogeneic transplantation regimens. Here we review the biology underlying the efficacy of yttrium-90 ibritumomab tiuxetan in NHL and present an overview of the clinical experience with this agent in NHL. Finally, we discuss the current role of yttrium-90 ibritumomab tiuxetan in the armamentarium of treatments for NHL and possibilities for incorporating it into future NHL treatment algorithms. Keywords: non-Hodgkin lymphoma, indolent, CD20, radioimmunotherapy, ibritumomab tiuxetan
format	article
author	McKinney MS Beaven AW
author_facet	McKinney MS Beaven AW
author_sort	McKinney MS
title	Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
title_short	Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
title_full	Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
title_fullStr	Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
title_full_unstemmed	Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
title_sort	yttrium-90 ibritumomab tiuxetan in the treatment of non-hodgkin lymphoma
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/b9627e99554348259522087327de8adb
work_keys_str_mv	AT mckinneyms yttrium90ibritumomabtiuxetaninthetreatmentofnonhodgkinlymphoma AT beavenaw yttrium90ibritumomabtiuxetaninthetreatmentofnonhodgkinlymphoma
_version_	1718399959237132288

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma

Ejemplares similares